Literature DB >> 29497

Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease.

M Serby, B Angrist, A Lieberman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 29497     DOI: 10.1176/ajp.135.10.1227

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  7 in total

1.  Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

Authors:  M E Stockton; K Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Bromocriptine and psychosis: a literature review.

Authors:  A Boyd
Journal:  Psychiatr Q       Date:  1995

Review 3.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

4.  Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy.

Authors:  H Y Meltzer; T Kolakowska; A Robertson; B J Tricou
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  Case report: acquired antisocial personality disorder associated with unilateral left orbital frontal lobe damage.

Authors:  C A Meyers; S A Berman; R S Scheibel; A Hayman
Journal:  J Psychiatry Neurosci       Date:  1992-09       Impact factor: 6.186

Review 6.  Psychological effects caused by drugs in overdose.

Authors:  L Evans
Journal:  Drugs       Date:  1980-03       Impact factor: 9.546

7.  Non-reproductive triggers of postpartum psychosis.

Authors:  Ian Brockington
Journal:  Arch Womens Ment Health       Date:  2016-10-08       Impact factor: 3.633

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.